A new biologic of this type, TL1A, allows for the very potent and selective neutralization of DR3 signaling and is potentially useful for the treatment of diseases involving TL1A deregulation, including diseases with a fibrotic component, such as asthma. The gene discussed is TNFSF15; the disease is asthma.